QR4: A Smarter Way to Predict Cardiovascular Risk

QR4: A Smarter Way to Predict Cardiovascular Risk

Cardiovascular disease (CVD) continues to be the leading cause of death in the UK and globally, despite decades of public health advances and improvements in treatment. As clinicians, our ability to accurately assess risk is central to preventing serious...
NICE Approval: A New Option for Endometriosis

NICE Approval: A New Option for Endometriosis

Ryeqo for Endometriosis: A New Treatment, A Renewed Responsibility With NICE’s recent approval of Ryeqo (relugolix, estradiol, norethisterone acetate) for use on the NHS, women of reproductive age now have a new treatment option for endometriosis. But this...
BMS Update: How to Safely Use HRT with Incretins

BMS Update: How to Safely Use HRT with Incretins

In April 2025, the British Menopause Society (BMS) published new clinical guidance to support healthcare professionals managing women who are prescribed both incretin-based therapies and hormone replacement therapy (HRT). This comes at a crucial time, as GLP-1...